Myriad Genetics, Inc. (NASDAQ:MYGN) saw some unusual options trading on Wednesday. Stock investors purchased 861 call options on the company. This is an increase of 806% compared to the typical volume of 95 call options.

Myriad Genetics stock opened at $44.86 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.19 and a quick ratio of 2.86. Myriad Genetics has a 12-month low of $27.23 and a 12-month high of $50.44. The stock has a market capitalization of $3.26 billion, a P/E ratio of 37.38, a price-to-earnings-growth ratio of 3.12 and a beta of 0.51.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings results on Tuesday, August 21st. The company reported $0.38 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.33 by $0.05. Myriad Genetics had a return on equity of 9.78% and a net margin of 17.69%. The business had revenue of $200.90 million during the quarter, compared to analysts’ expectations of $195.93 million. During the same period in the previous year, the business posted $0.30 earnings per share. The firm’s revenue for the quarter was up .7% compared to the same quarter last year. As a group, sell-side analysts predict that Myriad Genetics will post 1.44 EPS for the current fiscal year.

MYGN has been the subject of a number of analyst reports. ValuEngine cut Myriad Genetics from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 21st. Morgan Stanley raised Myriad Genetics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $35.00 to $55.00 in a report on Wednesday, July 11th. Bank of America lifted their price objective on Myriad Genetics from $20.00 to $31.00 and gave the company an “underperform” rating in a report on Monday, July 16th. BidaskClub cut Myriad Genetics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 21st. Finally, Piper Jaffray Companies lifted their price objective on Myriad Genetics to $38.00 and gave the company a “neutral” rating in a report on Wednesday, August 22nd. Four equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. Myriad Genetics has an average rating of “Hold” and an average price target of $41.10.

Several institutional investors have recently added to or reduced their stakes in the stock. CHICAGO TRUST Co NA bought a new position in shares of Myriad Genetics in the third quarter valued at about $230,000. United Services Automobile Association raised its holdings in shares of Myriad Genetics by 8.0% in the second quarter. United Services Automobile Association now owns 36,961 shares of the company’s stock valued at $1,381,000 after buying an additional 2,746 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Myriad Genetics by 2.7% in the second quarter. Northern Trust Corp now owns 1,801,882 shares of the company’s stock valued at $67,337,000 after buying an additional 47,994 shares during the last quarter. Public Employees Retirement System of Ohio raised its holdings in shares of Myriad Genetics by 7.2% in the second quarter. Public Employees Retirement System of Ohio now owns 155,885 shares of the company’s stock valued at $5,825,000 after buying an additional 10,503 shares during the last quarter. Finally, GHP Investment Advisors Inc. raised its holdings in shares of Myriad Genetics by 4.5% in the second quarter. GHP Investment Advisors Inc. now owns 53,290 shares of the company’s stock valued at $1,991,000 after buying an additional 2,305 shares during the last quarter.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

Further Reading: How to Invest in Growth Stocks

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.